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Interleukin-13 (IL-13) as a pleiotropic cytokine acts through the IL-13Ra1/
IL-4Ra complex to induce activation responses which contribute to the infl amma-
tory diseases. Genetic polymorphisms in IL-13 and its receptor components have 
been proved to be associated with higher disease prevalence rates. Animal models 
such as in IL-13 defi cient mice and transgenic animals also have been confi rmed the 
critical role of this cytokine in the immune responses, mostly by IL-13 neutralization 
and IL-13/IL-4 dual neutralization strategies. This review highlights IL-13 structure 
as well as its pivotal roles in the normal physiologic and pathologic states. It is fol-
lowed by a section on the recent fi ndings on IL-13 receptors and signalling mecha-
nisms to briefl y summarize its functions in the immune systems. IL-13 roles in the 
human diseases such as asthma, systematic sclerosis, and some infl ammatory dis-
eases are described concisely. Finally some of the ongoing therapeutic applications 
are presented to comprehensively review IL-13 mediator roles.
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Introduction
Interleukin-13 (IL-13) is a cytokine secreted by activated T-helper 2 (Th2) 
cells. It is a counter-regulatory system for the type I immune response and has 
emerged as an important regulator of type II cytokine-mediated immune re-
sponses [1]. In the 80s, IL-13 was observed as a protein which is preferentially 
produced by activated mouse Th2 cells [2–4]. Several years later, three groups 
cloned the complementary DNA (cDNA) for human IL-13 [5–7].
IL-13 has a single open-reading frame with 132 amino acids. It contains a 
20-amino-acidsignal sequence which is cleaved from the mature secreted pro-
tein. IL-13 is secreted as a 10-kd unglycosylated species [8] that has been demon-
strated by the transfection of the cDNA into COS-7, i.e. the cells being CV-1 
(simian) in origin, and carrying the simian virus 40 (SV40) genetic materials.
Crystallography technique allowed us to gain more information about the 
function of IL-13 and its receptors. By using this technique, IL-13 has been ob-
served to have a 4α-helical hydrophobic bundle core which is an indication of 
the class of type I cytokines and it has an up-up-down-down overall topology 
(Fig. 1) [9]. For a more detailed review on the structure of this cytokine (IL-13) 
refer to the paper by Eisenmesser et al. [10] (Fig. 1).
The gene encoding IL-13 is comprised of 4 exons and 3 introns and it is 
located 12 kb upstream of the gene encoding IL-4 on chromosomal region 5q31 
(Fig. 2) [11]. Gene encoding IL-4 and IL-13 both are in the same orientation [12]. 
5q31 also contains the genes encoding IL-3, IL-5, IL-9 and granulocyte-mac-
rophage colony-stimulating factor (GM-CSF)-4 and -12. This chromosomal re-
gion has been linked with asthma [13–16] which we will discuss later. It is also 
worth mentioning that IL-13, IL-3, IL-5, IL-4, and colony-stimulating factor 2 
(CSF2) form a cytokine gene cluster on chromosome 5q (Fig. 2).
IL-4 and IL-13 share many similarities yet they present some important 
differences. To name a few, IL-13 does not cause proliferation of T cells or dif-
ferentiation of naive T cells towards Th2 cells as IL-4 does, and activation of 
mast cells by IL-13 is weaker than by IL-4 [8]. The 25-amino-acid hydrophobic 
structural core is completely conserved between IL-13 and IL-4, with only some 
conservative hydrophobic substitutions, however IL-13 only shares 25% homol-
ogy with IL-4 at the amino acid level [18]. IL-4 contains 3 disulfi de bridges 
and in contrast mass spectrophotometry revealed that L-13 contains only two 
bridges [19].
IL-13 has effects on immune cells that are similar to those of the closely 
related to IL-4. However, IL-13 is suspected to be a more central mediator of the 
pathophysiologic changes induced by allergic infl ammation in many tissues.
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Figure 1. Top) Structure of IL-13 with a 4α-helical hydrophobic bundle core which is an indication 
of the class of type I cytokines as rendered by Protein Data Bank in Europe (PDBe); 
Bottom) The up-up-down-down overall topology of IL-13. Three loops connect four helical regions, 
i.e. A, B, C, and D together. A disulfi de bond connects AB loop to BC loop. 
AB and CD loops are connected by a short β-sheet which has not been shown in the fi gure [10]
Figure 2. IL-13 Gene in genomic location. It is located 12 kb upstream of the gene encoding IL-4 
on chromosomal region 5q31; Adapted from University of California Santa Cruz Genome Browser [11]
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Historically, researchers hypothesized that another ligand signalling 
through the IL-4 receptor complex was responsible for mediating the effector 
arm of the immune response. Therefore IL-13 was suggested as a plausible 
 candidate player in the development of allergic airway responses due to a high 
degree of similarity between IL-13 and IL-4. Thereafter, it was demonstrated 
separately by two groups of researchers that specifi c blockade of IL-13 by admin-
istration of a soluble form of the IL-13Ra2 chain to allergen-challenged mice, in 
a way that only binds with IL-13 and not IL-4, reversed Airway HyperRespon-
siveness (AHR) and mucus production [20]. It also has been shown that acute 
administration of IL-13 itself was suffi cient to recapitulate many features of the 
allergic phenotype, such as AHR, eosinophilic infl ammation, and mucus cell hy-
perplasia in non-immunized mice or recombination-activating gene-defi cient 
mice [21, 22].
IL-13 actions have been analysed both on the non-immune and immune 
cells with more focus on the former. IL-13 actions on resident cells in the bron-
chial tissues have been characterized with a focus on the involvement of IL-13 in 
the pathogenesis of bronchial asthma. Several studies demonstrated that IL-13 
induces production of transforming growth factor beta (TGF-β) [23, 24], eotax-
in-3 [25], and mucin [26]. It also has been shown that human and mice IL-13 in-
duce calcium-activated chloride channel 1 (hCLCA1) and mCLCA3 (Gob-5) 
[27–31] in bronchial epithelial cells, respectively.
In addition, IL-13 has a wide range of roles on the fi broblasts inducing the 
expression of integrins [32], periostin [33] and proliferation [34]. It also has di-
verse functionality on the non-immune cells by inducing the production of eo-
taxin [35, 36] and enhancing contractility [37, 38] in bronchial smooth muscle 
cells. To mark the importance of the role of IL-13 in human disease we should 
note how its receptors function and what are the common signalling pathways 
and mechanisms. Following the next section we describe IL-13 role in Asthma, 
Systemic Sclerosis, Gastrointestinal Infl ammatory Diseases (such as Ulcerative 
Colitis, Eosinophilic Oesophagitis, and Intestinal Fibrosis), and also its anti-tu-
mour immunity role in sections 3, 4, 5, and 6, respectively.
IL-13 receptors and signalling
As mentioned, IL-13 is recognized as a type I cytokine and it signals 
through the type I cytokine receptors. Some of the well-known features of the 
type I cytokine receptors are the representation of four conserved cysteine resi-
dues, a W-S-X-W-S motif, fi bronectin type II modules in the extracellular do-
main, and proline-rich box regions in the intracellular domain. The latest feature 
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is important for binding of Janus tyrosine kinases (JAK) [9]. Despite no intrinsic 
kinase activity of these receptors they have constitutively associated with 
JAKs. This characteristic eventually results in the recruitment of downstream 
signalling molecules. Type I cytokine receptors recognize and respond to the 
cytokines with four α-helical strands and they form heterodimers. In total, four 
receptors between IL-4 and IL-13 have been found so far, i.e. IL-4Rα, Type II 
IL-4R, Type II IL-13R, and IL-13Rα2 that are described in the following sec-
tions.
IL-4Rα
IL-4Rα is a component of both type I and type II IL-4 receptors [17]. It is 
a 140-kd protein chain which binds IL-4 with high affi nity and both IL-13 and 
 IL-4 employ it as a component of their receptors. The cDNA of this chain en-
codes an open-reading frame of 825 amino acids [39, 40]. The frame is contained 
a 25-amino-acid signal sequence. IL-4Rα also shows type I cytokine receptor-
like features with 4 conserved cysteines and the W-S-X-W-S motif in the extra-
cellular domain.
It also contains a single transmembrane domain. A long intracellular do-
main is included in IL-4Rα which contains a membrane proximal Box-1 se-
quence. This membrane serves as a docking site for JAK1 and 5 conserved tyros-
ine (Y) residues at positions Y497, Y575, Y603, Y631, and Y713.
Association of IL-4Rα with the common γ chain (γc), which is also a com-
ponent of the receptors for IL-2, IL-7, IL-9 and IL-15 result in the type I IL-4 
receptors [9]. The γc is important for the signalling of type I receptor however it 
does not bind neither with IL-4 nor with IL-13.
Studying the potent IL-4Rα antagonists revealed that IL-4Rα is also a com-
ponent of the IL-13 receptor. These tested antagonists were observed to block 
IL-4Rα. Moreover, they were found to inhibit both IL-4 and IL-13 responses [41, 
42]. Further studies demonstrated that both IL-4 and IL-13 responses can be in-
hibited by blocking antibodies against IL-4Rα [43, 44].
Type II IL-4R/IL-13R
The γc has a signifi cant role in the signalling of multiple cytokines and the 
mutated γc has been shown to cause several types of immunodefi ciency in human 
[45]. IL-4 and IL-13 responses have been reported to remain intact even in the 
absence of γc in immunodefi ciency patients [46]. These observations suggested 
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that an alternate receptor for IL-4 and IL-13 might exist. Today this alternative 
receptor known to be comprised of IL-4Rα and IL-13Rα1, and it is a heterodimer. 
Although the γc is not a component of the type II IL-4/IL-13 receptor, there is 
some evidence that overexpression of the γc might affect IL-13 function [47]. 
Nonetheless the biologic relevance of this observation is unclear.
We should note that IL-13 has two cognate receptors: IL-13Rα1 and 
 IL-13Rα2. They both are members of the haematopoietin receptor superfamily 
which share 37% homology at the amino acid level. In vitro expression has re-
vealed that they both specifi cally bind IL-13 [48–51]. IL-13Rα1 is a shared com-
ponent between IL-13 and IL-4 and it serves as an alternative receptor for IL-4.
A 427-amino-acid sequence can be encoded by the proper cDNA for hu-
man IL-13Rα1 where the sequence is comprised a 26-amino-acid signal sequence. 
IL-13Rα1 is a glycosylated protein with 65- to 70-kd and it binds IL-13 with low 
affi nity by itself. However when this cognate receptor paired with IL-4Rα it 
binds IL-13 with high affi nity [51]. Subsequently it forms a functional IL-13 re-
ceptor that signals effectively.
An imbalance can occur between IL-13Rα1 and the γc for IL-4Rα with 
overexpression of the γc by means of transfection. The imbalance could result 
in an increase of IL-4Rα/γc heterodimers and a compensatory diminishing of 
 IL-13Rα1/IL-4Rα heterodimers. This response effectively reduces the IL-13 sig-
nalling. However, we should keep in mind that the γc is not a component of the 
IL-13 receptor complex [52].
Although IL-4 and IL-13 are not the same in the term of species specifi c 
behaviour, yet IL-4Rα and IL-13Rα1 interact completely species specifi c. This 
has been evidenced by the fact that human IL-13Rα1 could associate only with 
human and not mouse IL-4α to form a functional receptor [53]. This species 
specifi city is thought to allow some specifi c inhibition of IL-13 function without 
infl uencing the IL-4 signalling and that can be benefi cial in the treatment of at-
opic disorders [54].
IL-13Rα2
The cDNA of human IL-13Rα2 encodes a sequence frame of 380 amino 
acids. Despite the presence of IL-13Rα2 transcripts in the brain, thymus, spleen, 
liver and lung [55, 56], this receptor is not required for the IL-13 functioning 
since the expression of both IL-13Rα1 and IL-4Rα is suffi cient for administrating 
cells to respond to IL-13.
Although the expression of IL-13Rα2 in vitro resulted in high-affi nity 
binding of IL-13, it was insuffi cient even in the presence of IL-4Rα to render re-
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sponsive cells to IL-13 [55]. IL-13Rα2 has been found to frequently exist as an 
intracellular molecule in large colonies of IL-13Rα2 in cultured monocytes, pri-
mary respiratory epithelium, respiratory epithelial cells, and primary human 
monocytes. These observations suggest the idea that this behaviour is not spe-
cifi c to a given cell type but rather it appears to be a widespread pattern [57].
After treatment of cells with interferon gamma (IFN-γ) the intracellular 
pools rapidly move to the cell surface. Based on this, a hypothesis has been pro-
posed for IL-13Rα2 role by which IL-13Rα2 acts as a decoy receptor and it can 
regulate IL-13 responses. This has been supported by observing IFN-γ-dependent 
upregulation of IL-13Rα2 that it was associated with diminished IL-13 signal-
ling. This mechanism provides the evidence that IFN-γ can regulate IL-13 re-
sponses. Although, some recent investigations have been reported that this re-
ceptor mediates IL-13 signalling under some circumstances which debates the 
concept of IL-13Rα2 as a decoy receptor [58, 59]. We should note that IL-4 and 
IL-13 receptors interact tightly and are likely under infl uence of similar triggers 
at various levels, although the confi rmation of these similarities requires further 
investigations.
Finally, in spite of many similarities, IL-13Rα1 and IL-13Rα2 have differ-
ent expression patterns on different cell types. IL-13 receptors are reported to be 
expressed on macrophages, human B cells, eosinophils, mast cells, endothelial 
cells, basophils, fi broblasts, monocytes, smooth muscle cells and respiratory epi-
thelial cells. Different studies have supported the membrane-bound protein na-
ture of IL-13Rα2, however fl ow cytometry measurements highlighted IL-13Rα2 
predominantly as an intracellular molecule in different human cell types such 
as monocytes, airway fi broblasts, and bronchial epithelial cells [60]. The results 
of several studies reported that IL-13Rα1 was expressed on several cells such as 
human skin fi broblasts, non-haematopoietic cells and monocytes [61]. It is also 
expressed on human Th17 cells but not on Th1 or Th2 cells [62] and is expressed 
on the M2 but not on the M1 subset of macrophages [63], which shows their di-
verse expression patterns on different cell types.
IL-13 signalling
IL-4 and IL-13 share common signalling pathways, consistent with the fact 
that they share common sub-units. IL-13 signalling uses the JAK-signal trans-
ducer (e.g. JAK1 and JAK3) and activator of transcription (STAT) pathway, spe-
cifi cally STAT6 which has been revealed by studying STAT6-defi cient mice 
[64, 65]. Figure 3 represents a schematic illustration of IL-4 and IL-13 receptors 
and signalling pathways.
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Stimulation of the complex by IL-4 and IL-13 result in the activation of 
signalling intermediates properties of IL-4 responses. This includes phospho-
rylation of IL-4Rα, insulin receptor substrate 2 (IRS-2), JAK1, and tyrosine ki-
nase 2 (TYK2) [66, 67]. Consequently, signalling through IL-4Rα/IL-13Rα1 is 
thought to occur through IL-4Rα.
Five conserved tyrosine residues have been identifi ed in IL-4Rα: Y497, 
Y575, Y603, Y631, and Y713. They are all essential in signalling through this re-
ceptor. Y497 is part of the IL-4R motif that is necessary for the recruitment of 
insulin receptor substrate-1 (IRS-1) and IRS-2 to IL-4Rα after IL-4 stimulation. 
Structure-function analyses also revealed its important role in IL-4-dependent 
cell proliferation [68]. Y713 is a part of an immunotyrosine-based inhibitory mo-
tif (ITIM). This tyrosine has been shown to be crucial in the negative regulation 
of IL-4 and IL-13 responses [69].
The rest of these tyrosines, i.e. Y575, Y603, and Y631, can act as STAT6 
docking sites. They act in a way that as long as one of them remains intact, IL-4- 
dependent gene induction remains intact too [70]. For a more detailed review on 
the similarities and differences between IL-13 and IL-4 receptors and signalling 
pathways refer to the paper by Callard et. al. [71].
Figure 3. Schematic illustration of IL-4 and IL-13 receptors and signalling pathways. 
IL-4 and IL-13 share common sub-units and as a result they also share common signalling pathways. 
Adapted with permission from Hershey [61]
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Comparing hIL-13 and hIL-13R with mIL-13 and mIL-13R
As mentioned, despite many similarities between mouse and human IL-13 
and their receptors, we should keep in mind the differences between those since 
most of the therapeutic attempts have been conducted on mice but we desire to 
apply them on humans. Here we briefl y compare these genes and their receptors.
Structurally, human IL-13 is located on chromosome 5q31 but mouse IL-13 
is located on chromosome 11 cytokine gene cluster [72]. Also both genes com-
prise four exons and three introns [73].
The hIL-13Rα2 and hIL-13Rα1 genes have been mapped to Xq24 [48] and 
Xq13 [74], respectively. Human IL-13Rα2 is consistent with a 26-amino-acid 
 signal sequence and its mouse counterpart has 59% shared amino acid identity 
[55] but both lack box-1 and -2 signalling motifs in their cytoplasmic domains. 
Although mice have ng/ml serum levels of soluble (s) IL-13Rα2, humans lack 
sIL-13Rα2 in serum [75].
Finally, in spite of many structural characteristics similarities between 
 IL-13 and IL-4, they have some important differences. Their ability to act across 
species is one of the most noticeable differences. IL-4 is absolutely species spe-
cifi c [18] while IL-13 is not [5, 8]. Human IL-4 acts only on human cells, and 
mouse IL-4 acts only on mouse cells. In contrast, mouse IL-13 acts on human or 
mouse cells with equal potency. Although IL-13 is believed to be species selec-
tive because human IL-13 has greater activity on human cells than on mouse 
cells.
In the previous sections we summarized the general characteristics, func-
tions, receptors, and signalling of IL-13. Following sections are aimed to briefl y 
cover some of the human diseases that are highly infl uenced by this interleukin.
IL-13 in asthma
Bronchial asthma is a chronic infl ammatory disease which is a complex 
disorder and has not yet been fully understood. While it has been recognized 
since ancient Egypt, its incidence, morbidity, and mortality have been increasing 
very rapidly in industrialized countries within the last few decades [76].
Wheezing, breathlessness, chest tightness, and coughing are the frequent 
episodic symptoms of asthma. It has been shown that a variety of stimuli, such as 
allergens (e.g. molds, house dust mites, and plant and animal debris), pharmaco-
logical agents (e.g. aspirin), infectious stimuli (e.g. particularly viruses), and 
 airborne pollutants (e.g. ozone and diesel exhaust particles) and irritants (e.g. 
 tobacco smoke) can trigger the above-named symptoms. The presence of lym-
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phocytes, eosinophils, and mast cells, along with epithelial desquamation, goblet 
cell hyperplasia, and thickening of the submucosa have been associated with the 
main physiologic abnormalities of the disease, namely airway obstruction and 
AHR [20, 77, 78].
The disease is thought to be caused by aberrant T-lymphocytes when it 
 responds to non-infectious environmental antigens. The existence of activated 
Th2 cytokine producing cells in the airway wall is recognized to be one of the 
important symptoms of asthma. Each of the Th2 cytokines (such as IL-4, IL-5, 
IL-9, and IL-13) likely contributes to the overall immune response directed 
against environmental antigens. In particular, the role of IL-13 in the regulation 
of the allergic diathesis has been well established by conducting initial studies in 
animal models of the disease. These studies provided strong evidences that IL-13 
was both necessary and suffi cient to cause all the known features of allergic 
asthma. This role of IL-13 was confi rmed to be independent of the role of other 
Th2 cytokines.
Variety of investigations on humans and animal models of allergic dis-
ease support the essential role of Th2 cytokines in the pathogenesis of allergic 
asthma. For instance CD4+ T cells that produce a Th2 cells’ pattern of cytokines 
[IL-4, IL-5, and IL-13] has been hypothesized to contribute signifi cantly in the 
pathogenesis of disease [79–81]. Figure 4 schematically shows the Th2 cytokines’ 
IL-4- and IL-13-induced responses.
Figure 4. Schematic illustration of the Th2 cytokines’ IL-4- and IL-13-induced responses. 
They induce the production of specifi c cytokines through STAT6 signal-activated pathways. 
Adapted with permission from Lukacs et al. [82]
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Early investigations were aimed to understand the role of IL-4, as a para-
digmatic cytokine, in Th2 differentiation and in regulation of the synthesis of 
the reaginic antibody IgE. Results of these experiments on IL-4-defi cient mice 
supported that the presence of IL-4 for the development of allergic symptoms is 
essential as no phenotype was observed in allergen-challenged IL-4 knockout 
(KO) mice [83]. These studies suggested while IL-4 is not critical for the effector 
phase of the response it is essential for the initial development and expansion 
of antigen-specifi c Th2 polarized cells [84, 85]. It was then hypothesized that 
another ligand signalling through the IL-4 receptor complex was responsible 
for mediating the effector arm of the immune response, and IL-13 was suggested 
as a plausible candidate player in the development of allergic airway responses.
It was demonstrated separately by two groups of researchers that specifi c 
blockade of IL-13 by administration of a sIL-13Ra2 chain (i.e. a soluble form of 
the IL-13Ra2 chain) to allergen-challenged mice in a way that binds only IL-13 
(and not IL-4) reversed AHR and mucus production. In addition to this demon-
stration, it was shown that acute administration of IL-13 was suffi cient to reca-
pitulate many features of the allergic phenotype, such as AHR, eosinophilic 
 infl ammation, and mucus cell hyperplasia in non-immunized mice or recombi-
nation-activating gene-defi cient mice [21, 22].
These features were recapitulated by targeted pulmonary overexpression 
of IL-13 in the murine lung, and the subepithelial fi brosis and the formation 
of Charcot–Leyden crystals were observed as well [86]. Allergen-induced AHR 
was reported to occur in the absence of IL-13 but it was not evident in the double 
 IL-4/IL-13 KO mice [87]. Thereafter, a study (that conducted with the same  IL-13 
KO mice) provided a conclusive evidence of the crucial role of IL-13 in mediating 
allergen-driven AHR and mucus hypersecretion [88]. All these observations sup-
port the idea that IL-4 is essential for the initiation of Th2 polarized immune re-
sponses to the allergenic peptides, while IL-13 alone may mediate the main phys-
iological consequences of the disease.
The fi eld has made great progress in understanding how infl uential Th2 
cytokine directs airway remodelling, airway infl ammation, and asthma patho-
genesis and IL-13 is recognized as a central mediator of human asthma [89, 90]. 
This role has been supported by showing that IL-13 polymorphisms, such as 
G+2044A [e.g. 91, 92], C-1112T [e.g. 93], and A-1512C [e.g. 92, 94], are strongly 
associated with asthma susceptibility [95] (see the review by Vercelli [96] for 
more details) and by fi nding that many IL-13-induced pathways are associat-
ed with asthmatic airway responses [97]. IL-13 and IL-4 activate STAT6 since 
they both share the IL-4Rα subunit in their receptors [98]. In addition, STAT6 
activation is crucial for the differentiation of T-cells into Th2 effector cells [99]. 
It regulates IL-13- and IL-4-induced production of Th2 cytokines such as eotaxin, 
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smooth muscle cells and fi broblasts [100]. Therefore, the IL-13/IL-4/STAT-6 
pathway has been proved to be a prominent player in asthma pathogenesis [89]. 
For a more detailed review on the role of IL-13 and its pathway and signalling in 
asthma and allergic disease read the paper by Ingram and Kraft [89].
IL-13 in systemic sclerosis
Systemic sclerosis (SSc, scleroderma) is an autoimmune disease or connec-
tive tissue disease which is characterized by vascular damage, infl ammation and 
progressive fi brosis of several internal organs and patients’ skin [101]. At the 
present time, it is unknown what causes SSc. However it has been shown that 
genetic, environment and abnormal immune function infl uence SSc prevalence, 
incidence, and progression that are subjects of active investigations [102, 103]. 
The prevalence of SSc is estimated to be 2 to 3 per 10,000 individuals in the USA 
and it is at a higher rate in the industrial countries [104].
The most prominent clinical signs of SSc is tissue fi brosis. It is believed to 
occur due to a reactive process which is likely a result of extracellular matrix 
(ECM) components overproduction [105]. The activation of ECM is thought to be 
a response to infl ammation, autoimmune attack and vascular damage. Through 
this process T cells play a signifi cant role in the pathogenesis of SSc. They derive 
some cytokines that implicate in the reparative infl ammatory and fi brotic pro-
cesses of SSc [102]. The serum and tissue of SSc patients show abnormal levels 
of these cytokines. They are involved in the different stages of the disease. For 
example, Th1 and Th17 cytokines are involved in the infl ammatory processes 
[106]. In addition, Th2 cytokines are considered profi brotic, and IL-13 plays sig-
nifi cant role in the pathogenesis.
Figure 5 illustrates how IL-13 can participate in the pathogenesis of SSc 
through different mechanisms. IL-13 is heavily implicated in the effector phase 
of infl ammation and fi brosis. It involves both directly and indirectly in the fi bro-
blast activation and stimulation of TGF-β, respectively [107]. The latter occurs by 
stimulation of macrophages to produce TGF-β which includes several distinct 
mechanisms such as the production of latent TGF-β and up-regulation of MMPs 
that cleave the LAP-TGF-β complex [108, 109], and via an IL-13Ra2 signalling 
pathway [110] (Figure 5).
The importance of IL-13 in SSc is also supported by several other investi-
gations [110, 112, 113]. For example Hasegawa et al. reported that SSc patients 
had higher serum levels of IL-13 compared to the control group and this higher 
expression of IL-13 was correlated with C-reactive protein levels and erythrocyte 
sedimentation rates. They concluded IL-13 could be one of the cytokines which 
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contribute to the disease progression [114, 115]. More recently Fuschiotti et al. 
found that peripheral blood effector CD8+ T cells from SSc patients show a shift 
toward a type 2 phenotype. This shift is determined by up-regulation of IL-13 
which correlates with the extent of skin fi brosis [116]. They also found that the 
level of IL-13 production compared to CD8+ T cells is lower and it is more vari-
able [116, 117]. This difference suggests that dysregulated IL-13 production is 
more a feature of CD8+ rather than CD4+ T cells in SSc. However the role of CD8+ 
T cells in SSc is not well understood since most studies have been focused on 
CD4+ T cells so far. Lack of a comprehensive study on CD8+ is mostly due to the 
strong MHC class II HLA association with certain forms of the disease and the 
presence of distinct and specifi c autoantibodies [118, 119].
Polymorphisms in the genes for IL-13 [110] and IL-13Ra2 [110] likely in-
crease the susceptibility to SSc. The single nucleotide polymorphism (C to T ex-
change) in the promoter of the IL-13 gene has been found to be associated with 
SSc in a cohort of Caucasian population [110]. Relatively few factors have been 
Figure 5. IL-13 plays signifi cant role in systemic sclerosis pathogenesis by several different 
mechanisms. It is heavily implicated in the effector phase of infl ammation and fi brosis. 
It involves both directly and indirectly in the fi broblast activation and stimulation of TGF-β, 
respectively. Adapted with permission from Fuschiotti [111]
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shown to regulate the IL-13 transcription and among them GATA-3 is recognized 
to be the most important factor regulating IL-13 gene expression [120–124].
GATA-3 is reported to effectively activate the proximal IL-13 promoter and 
a putative GATA-3 binding site identifi ed to contain therein [125]. Defects in the 
molecular control of IL-13 production are likely to play an important role in the 
pathogenesis of diffuse cutaneous SSc [126]. Analyzing the extracted GATA-3 
from the freshly isolated naïve CD8+ T cells from SSc patients shows a signifi -
cantly higher level in comparison to the control group. Up-regulation of GATA-3 
expression has also been demonstrated in the transcriptional profi ling of periph-
eral blood cells from early SSc patients [127]. Another role of GATA-3 in the 
regulating IL-13 expression has been observed when silencing of GATA-3 with 
siRNA signifi cantly reduced GATA-3 and IL-13, but IFN-γ levels in CD8+ T cells 
from SSc patients remained invariant [126].
Moreover, the GATA-3 expression and functions have shown to be con-
trolled by multiple factors [128] including the Th1-specifi c transcription factor 
T-bet. This factor induces IFN-c production [129–131] and inhibits Th2 cytokines 
such as IL-13 [132, 133], by antagonizing GATA-3 expression and/or function 
[134]. The Th1/Th2 polarization is believed to be determined by the mutually 
exclusive expression of T-bet and GATA-3 [1]. T-bet polymorphisms have shown 
to be associated with increased risk of SSc [135]. More recently, IL-33 was found 
to stimulate mouse bone marrow-derived eosinophils to secrete IL-13 and pro-
mote cutaneous fi brosis [113]. According to these observations the IL-13 overpro-
duction in SSc may result from excess IL-33 stimulation. These fi ndings suggest 
that the molecular control of IL-13 production by CD8+ T cells is abnormal in SSc 
patients. It is also believed to be critical for predisposing patients to more severe 
forms of the disease. Subsequently GATA-3 overexpression is likely one of the 
most important drivers in the pathogenesis of SSc.
IL-13 in gastrointestinal infl ammatory diseases
As mentioned IL-13 is a cytokine that is recognized mostly by its roles 
in the allergic and other infl ammatory diseases [136]. The main infl ammatory 
role of this cytokine is against helminthic infections as a part of the gut mu-
cosal immune response system. IL-13 acts in mucosal immunity as a factor that 
stimulates goblet cells to produce mucus, attracts eosinophils by local eotaxin to 
 release and increase the IgE production. In addition, IL-13 has a possible contri-
bution to increase gut motility and epithelial secretion [137, 138].
IL-13 KO mice show more durable parasite expulsion times following the 
experimental intestinal nematode infection [139, 140]. IL-4Rα and STAT6 defi -
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cients show a similar pattern but IL-4 defi cient mice do not follow the pattern. 
These observations led to this conclusion that IL-13 likely has signifi cant role in 
antihelminth immunity. In addition, CD4 cells from Trichuris muris infected 
wild-type mice are frequently reported to be able to transfer resistance to infec-
tion in T and B cell defi cient (SCID) mice [141]. Therefore it is believed that CD4+ 
T cells are the major source of gut mucosal IL-13 in helminth infections.
IL-13Rα1 also can be found constitutively in gut epithelium. However it is 
remained unanswered whether IL-13 always plays a signifi cant homeostatic role 
or this cytokine only acts in infection and/or injury. On one hand, IL-13 limits 
Th17 infl ammation by blocking IL-17 production which is a subsequent result 
of increasing IL-10. This effect has been proved by investigating related respons-
es on both human and mouse cells which suggests a homeostatic role of IL-13 in 
the gut [142]. On the other hand, IL-13 may play an important role in limiting 
evolving colitis injury. Through this process IL-10 KO mice are susceptible to 
severe T muris gut infection. This occurs when the IL-13Rα2 decoy receptor is 
also deleted which effectively increases the bioavailability of IL-13. Therefore 
mortality and induction of colitis increase the protection signifi cantly [143, 144].
We should note here that IL-13 has been stated as a component of various 
types of mucosal infl ammation. This includes ulcerative colitis and eosinophilic 
oesophagitis (EO) in addition to allergic asthma, and many other diseases bear-
ing fi brosis [136] that we briefl y cover in the following sections.
Ulcerative colitis
IL-13 is known as an effector cytokine that drives infl ammation in ulcera-
tive colitis. This role has been shown by using a suit of murine models of ulcera-
tive colitis from confi rmed excess production of IL-13 in human disease [145]. 
A consequence of increasing the hallmark cytokine of the Th2 response (IL-4) is 
a signifi cant increase in the produced IL-13 by lamina propria mononuclear 
cells. The lesion can be prevented effectively by depleting NKT cells and also by 
administration of an IL-13Rα2-Fc fusion protein. Therefore the NKT cells are 
the major source of the IL-13 that contributes to the infl ammation [146].
Administration of intratracheal α-galactosylceramide analogue in mice 
leads NKT cells to induce a Th2 infl ammatory response (i.e. IL-4, IL-5 and 
 IL-13) to the other antigens. This induction suggests that NKT cells are important 
components of innate IL-13 responses [147]. IL-13 level in patients with active 
ulcerative colitis is higher which is resulted from lamina propria mononuclear 
cells. They also have shown increased epithelial pSTAT6 in comparison to the 
active Crohn’s patients and healthy controls [148, 149].
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The deleterious effects of IL-13 on the epithelial barrier and colonic epithe-
lial cells occur when the production of IL-13 in ulcerative colitis is extremely 
high. IL-13 has been reported to activate the proapoptotic molecule cysteine- 
aspartic acid protease 3 (CASP3) in mouse colonic epithelial cells as well as in 
patients with active ulcerative colitis [150]. In vitro studies show that IL-13 can 
induce epithelial cell apoptosis and it also causes disruption in tight junction by 
inducing claudin 2 [151]. These observations support the idea that IL-13 is a po-
tentially valuable target for therapeutic objects in ulcerative colitis.
IL-13 in eosinophilic oesophagitis
Eosinophilic oesophagitis (EO) is a disease characterized by infi ltration of 
the oesophageal mucosa with allergic infl ammatory like conditions [152]. The 
role of IL-13 in the induction of typical lesion of EO is demonstrated by investi-
gating the animal models. For instance, subsequent eosinophilia of the oesopha-
gus after nasal or tracheal administration of IL-13 was observed in the animal 
models [153], and aeroallergen induction of an EO-like lesion, in both IL-13 and 
STAT6 defi cient mice, failed to develop the oesophageal infl ammation [154]. 
Similarly, induction of IL-13 overexpression in the lungs resulted in the 
 oesophageal eosinophil infi ltration and oesophageal tissue remodelling [155]. 
Murine oesophageal tissue, after incubation with IL-13, produces several factors 
that are important in the development of EO [156]. Clear cytokine profi le in EO 
indicates signifi cant upregulation of IL-13 and IL-5 expression [157]. Elevated 
levels of IL-13 and IL-5 are also reported to be detectable in the plasma of chil-
dren with food allergy and EO [158].
Although these evidences of the existence of correlation between IL-13 
and the development of EO are signifi cant but further investigations are required 
to comprehensively understand the underlying mechanisms by which we are 
able to link the IL-13 to the related diseases.
IL-13 in intestinal fi brosis
Tissue fi brosis such as hepatic fi brosis [159], progressive systemic sclerosis 
[115, 160] and idiopathic pulmonary fi brosis [161] are deleterious outcomes of 
 IL-13 exposure. This has been proved by demonstrating the relation between tis-
sue remodelling with animal models of EO, bleomycin induced pulmonary fi bro-
sis [162] and allergic asthma [86, 155]. A massive IL-13 production has been ob-
served in the 2-, 4- and 6-trinitrobenzenesulfonic acid (TNBS) model of colitis 
after administration of TNBS in the examined mice.
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Scharl et al. reported IL-13 induces genes involved in cell invasion that 
lead to fi stula formation through tissue [163]. It has been also confi rmed that 
TGFβ highly expresses and induces IL-13 by lamina propria fi broblasts. Taken all 
these observations together it can be concluded that IL-13 is likely an important 
target for antifi brotic therapies in specifi c settings [164].
IL-13 in anti-tumour immunity
In the last decade many researches have been conducted to understand 
mechanisms by which cancer cells evade the immune system. It is mostly be-
lieved that immune deviation toward Th1 response, including activation of CD8+ 
cytotoxic T cells (CTLs), results in tumour rejection whereas divergence toward 
Th2 response prevents tumour rejection [165]. Anti-tumour immunity via Th1 
and CTL is down-regulated in different ways in tumour-bearing animal models 
and cancer patients. Since immune deviation toward Th2 suppresses Th1-activa-
tion, it is believed that induction of a Th2 immune response is one of the mecha-
nisms that negatively affect tumour immune responses. IL-13 as a Th2 secreted 
cytokine plays a critical role in many aspects of immune regulation. IL-13 has 
central role in immunoregulatory pathway in which NKT cells suppress tumour 
immunosurveillance [166].
IL-13 in negative regulation of immunosurveillance
Several mechanisms are thought to be responsible for the immunosup-
pression by diminishing Th1-responses such as DTH or CD8+ CTL activity in 
cancer cases. One hypothesized mechanism is to skew immune response against 
tumour toward Th2 suppresses Th1 immune responses. Researches have been 
investigating experimental methods to establish this hypothesis. A frequently 
used experiment is studying STAT6-defi cient mice. In this experiment, STAT6 
KO mice (that are defi cient in IL-4Rα-mediated signalling) showed tumour 
 regression that demonstrates a tumour supportive role for IL-13 and/or IL-4 
[167–169].
IL-4Rα KO and STAT6 KO mice have been observed to reject the tumours 
but IL-4 KO has not been reported to act similarly. This implies the signifi cant 
immunosuppressive role of IL-13 as a tumour immunosurveillance inhibitor in 
comparison to IL-4. Inhibiting of IL-13 by soluble IL-13Rα2-Fc leads to the tu-
mour rejection in both IL-4 KO mice and wild-type mice. Therefore IL-13 is 
likely to be the dominant cytokine which negatively regulate CTL-mediated 
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 tumour immunosurveillance. In addition, NKT cell-defi cient CD1d KO mice 
 after tumour induction are highly resistant to the tumour and consequently IL-13 
production by T cells would be reduced signifi cantly. This experiment supports 
results from another study which reported CD4+ NKT cells from tumour-bearing 
mice showed up-regulated IL-13 production.
Both experiments which we gave here as examples indicate that CD4+ 
NKT cells act as the dominant source of IL-13, and CD4+ T cells produce very 
low levels of IL-13 in tumour bearing mice. They concluded that the IL-13 pro-
duced by CD4+ NKT cells down-regulates CD8+ CTL-mediated tumour immu-
nosurveillance through the IL-4Rα-STAT6 pathway [169]. However, one may 
speculate how IL-13 represses CTLs since T cells do not express type II IL-4 
receptors, although they express the type I IL-4R.
New fi ndings are consistent with the speculation that IL-13 from NKT 
cells activates CD11b+Gr-1+ myeloid cells to produce TGF-β in tumour-bearing 
mice, and it acts directly on CD8+ T cells to negatively regulate tumour-specifi c 
CTL [170]. This down-regulation of tumour immunosurveillance by IL-13 also 
has been observed in a colon carcinoma lung metastasis model, in which tumour 
development was partially inhibited in CD1d KO mice and mice treated with 
 IL-13 inhibitor, but has not been observed in IL-4 KO mice [166].
Along with these fi ndings, by studying fi brosarcoma and colon carcinoma 
an experiment on the orthotopic breast tumour model with lung metastasis re-
vealed that STAT6 KO mice and NKT cell-defi cient CD1d KO mice are highly 
resistant against lung metastasis [171]. It has been reported that IL-13inhibitor 
treatment of HER-2/neu transgenic mice can delay the progression of spontane-
ous autologous mammary carcinomas [166]. These data collectively confi rm this 
notion that negative regulatory pathway by NKT cells and IL-13 inhibits immu-
nosurveillance against different types of tumours and also blockade of this path-
way may intensify the effi cacy of anti-tumour vaccines in the future [172, 173]. 
In contrast to these observed roles, which introduce IL-13 as a cytokine that 
modulates adaptive immune responses, there are some indications that show lo-
cal delivery of IL-13 at the tumour site induces tumour regression or rejection 
mediated by granulocytes and macrophages [174, 175].
Direct effects of IL-13 on tumours
In addition to these indirect effects of IL-13 on tumours it could affect tu-
mours directly as well. Type II IL-4R is expressed on a wide range of cells in-
cluded tumour cells. Several indications of type II IL-4R on tumour cells have 
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been reported including lymphoma [176], renal cell carcinoma, glioblastoma 
[177], head and neck cancer [177, 178], hepatoma [179], pancreatic cancer, breast 
cancer [174], prostate cancer [180], and colon cancer [181]. Among them the role 
of IL-13 and its receptor is more studied in Hodgkin‘s lymphoma/Reed-Stern-
berg cells (H/RS) [182]. According to these studies IL-13 in H/RS cells acts as 
an autocrine growth factor in vitro and IL-13 blocking shows signs of apoptosis 
induction [183]. In addition, the H/RS cell lines have been observed to activate 
STAT6 which implies the presence of signal transduction through the receptor. 
These observations were made in both in vitro in tumour cell lines and in vivo 
by examining biopsies of H/SR [184]. The expression of IL-13 and phospho-
STAT6 is exclusive to H/RS and not to the other types of lymphoma. IL-13 pro-
duction by H/RS may also affect the immune response to the tumour in addition 
to its autocrine effect [185].
One of the other mechanisms of triggering tumour metastasis is the reduc-
tion of cell–cell adhesion. In the colon cancer cell line, which expresses the type 
II IL-4R, both IL-4 and IL-13 negatively regulate the expression of two mole-
cules that are responsible for the cell adhesion, i.e. E-cadherin and carcinoembry-
onic antigen [181]. In some occasions IL-13 up-regulates VCAM-1 which is ob-
served in the glioma cell lines which expresses IL-4Rα, IL-13Rα1, and IL-13Rα2 
[186]. IL-13 also directly acts on B chronic lymphocytic leukaemia (B-CLL), 
however IL-13 does not act as a growth factor as similar as in H/SR but rather it 
inhibits IL-2-induced proliferation and apoptosis [176]. In summary, by several 
mechanisms, IL-13 can promote survival of certain types of tumours through 
direct action on the tumour or acting through suppression of immunosurveil-
lance.
Here we briefl y summarized the importance of IL-13 only in some of hu-
man diseases, but various studies have shown that IL-13 probably has much  wider 
infl uence on variety of human diseases. To name a few, we [187] reported IL-13 
was present in serum from patients with active primary visceral leishmaniasis 
(VL). They indicated that IL-13 serum level drops to control level after success-
ful treatment. Chen et al. [188] suggested that IL-13 C-1112T promoter polymor-
phism is associated with the risk of chronic obstructive pulmonary disease 
(COPD) in Arabian population by conducting a meta-analysis. More recently, we 
showed signifi cant association of IL-13 polymorphisms with Multiple Sclerosis 
(MS) in Iranian patients [189]. We concluded that both promoter and coding re-
gions of  IL-13 gene affect susceptibility to MS.
Although, enormous evidences have been presented to support crucial role 
of IL-13 gene in variety of human diseases but further investigations are required 
to prove it, especially in non-allergic diseases.
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Therapeutic applications
After reviewing some of the important roles of IL-13 in human diseases it 
naturally follows to use this interleukin for therapeutic purposes. This paradigm 
has been extensively developed since IL-13 was discovered 28 years ago [4]. 
For instance, early attempts show IL-13 blockade by sIL-13Rα2-Fc [21, 22] or 
by antibody [190] in murine systems limits asthmatic responses. The limitation 
of asthmatic responses includes but not limited to AHR, eosinophilia, mucus 
production, IgE generation, and fi brosis. Based on this limiting act several mono-
clonal antibodies, that targeting IL-13, are being developed for the treatment of 
asthma and several more are expected to be developed after preclinical develop-
ment stage [191–193].
Airway challenge with Ascaris antigen triggers early and late phase bron-
choconstriction responses in sheep sensitized to the nematode parasite. Airway 
hyperresponsiveness to carbachol also has been observed. To protect the animals 
from the late phase bronchoconstriction (following airway challenge with As-
caris antigen, and inhibit Ascaris-induced airway hyperresponsiveness) we may 
apply human IL-13 antibody IMA-638 (a.k.a. Anrukinzumab). This antibody 
should be delivered by intravenous infusion 24 hours prior to antigen challenge 
[194]. Early Anrukinzumab delivery reduces the infl ammatory infi ltrate [195]. 
It can also signifi cantly reduce the early phase response when the usage of the 
antibody is at high dose [194]. In cynomolgus monkeys Ascaris-sensitizing shows 
manifestations such as that segmental lung challenge with the antigen induces an 
eosinophilic airway infl ammation.
Therapeutic applications of IL-13 were progressed by fi nding several new 
peptide-based vaccines for IL-4 and IL-13. They have been developed and uti-
lized in mouse asthma models. Crystallization of the IL-4/IL-4Rα revealed its 
detailed structure and it has been suggested a peptide epitope of IL-4 that lies at 
the contact site with IL-4Rα. The peptide was conjugated to truncated hepatitis B 
core antigen as carrier. This vaccine raised high titers of IgG to IL-4 which con-
sequently led to reduction in IgE antibodies to ovalbumin (OVA), bronchoalveo-
lar lavage fl uids (BAL F) infl ammation, AHR to methacholine [196].
In order to produce peptide-based vaccine for IL-13 a similar method was 
used and mice were immunized by applying a peptide corresponding to a phylo-
genetical region which is believed to contain a receptor interaction site. The 
 IL-13-immune mice demonstrated reduced IgE titres, airway infl ammation, mu-
cus metaplasia, and AHR to methacholine after OVA immunization and chal-
lenge [194]. All these observations suggest that in mice, asthmatic responses can 
be well controlled by the presence of antibody to either IL-4 or IL-13.
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Although these experiments were all on mice but several companies have 
already started clinical trials with the Food and Drug Administration’s (FDA) 
approval, achieving Fast Track designation and have been conducted successful 
clinical trials. As an example, one of these researches has been based on a new 
fi nding about IL-13 which high-grade astrocytomas (i.e. the deadliest form of 
brain cancer and perhaps the most prevalent one) overexpress IL-13 receptors 
signifi cantly higher than its level in normal tissue [197, 198]. Debinski et al. [197]
developed mutated IL-13 based compounds which bind IL-13 receptors more 
tightly than normal tissue IL-13 receptors in high-grade astrocytomas (Fig. 6). 
In addition, the discovered compounds do not bind normal cell receptors. This 
behaviour directs towards more restrictive IL-13 receptors which can be ex-
pressed on cancer cells.
These advances are believed to help the treatment of brain cancer from dif-
ferent aspects [199]. First, by combining the targeting molecule, i.e. a mutated 
IL-13, with a cellular toxin it would be possible to make a “smart bomb” which 
delivers the cytotoxin that is specifi c to cancer cells. Second, by attaching a ra-
Figure 6. Mutated IL-13 based compound binds IL-13 receptors more tightly than normal tissue 
IL-13 receptors in high-grade astrocytomas [198, 199]. This compound does not bind normal cell 
receptors which promises more restrictive IL-13 receptors that can be expressed on cancer cells
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dioisotope (which is suited for medical imaging) to the target molecule it would 
be possible to make diagnostic tests for brain cancer and follow-up tests after 
treatment with a more accurate method. Third, by taking a quick assessment of 
the compound binding we could determine whether over-expression of IL-13 is 
present which marks a high-grade astrocytoma. That would make an easy yet 
relatively cheap diagnostic kit for brain tumour tissue. And fi nally, instead of at-
taching a cellular toxin we could attach a targeting molecule to a small molecule 
with anti-tumour properties or a conventional chemotherapeutic. This would help 
to decrease toxicity of tissue and having potentially more effective tumour pen-
etration.
Nowadays, IL-13 therapeutic applications in asthma are more advanced 
than ever. Table I chronologically highlights some of the fi ndings in this fi eld 
which led to the fi rst successful clinical trial with IL-13/IL-4 inhibitor in asthma 
[200].
In 2011, Corren et al. [201] conducted the fi rst successful clinical trial by 
hypothesizing that anti-IL-13 therapy would benefi t patients with asthma who 
had a pretreatment profi le consistent with IL-13 activity. Although, IL-4 and IL-13 
are favourable targets for therapeutic applications in asthma, but agents targeting 
either IL-4 or IL-13 alone have shown limited effi cacy in human clinical studies 
[202]. Subsequently, dual neutralization of IL-4 and IL-13 has been hypothesized 
to be a more promising therapeutic approach for asthma and allergy [203, 204].
Table I. Summarizing some of the fi ndings in IL-13 therapeutic applications in asthma 
which led to the fi rst successful clinical trial with IL-13/IL-4 inhibitor by applying a random-access, 
cross-disciplinary approach. Partially adapted from Grunig et al. [200]













Cloning of IL-13 receptors Gene association studies: IL-13, IL-4, IL-4Rα
Preclinical IL-13 inhibitors: 
Mutant-antagonist, IL13Rα2
Biomarkers
First clinical trials with 
IL-13/IL-4 inhibitors
Neutralizing 
reagents for clinical use
BiomarkersBiomarkers
Various animal 
effi cacy & toxicology
  Successful clinical trial
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In 2013, Redpath et al. [205] developed human neutralizing monoclonal 
antibodies against human IL-13Rα1 subunit in vitro by utilizing the dual neu-
tralization approach. They produced an antibody to the third ectodomain (D3) of 
IL-13Rα1 which forms an essential binding site for both IL-13 and IL-4. This 
therapeutic approach could effectively neutralize the actions of both cytokines. 
This method comprises promising results and it may play a signifi cant role in the 
prevention and treatment of asthma in the future.
The conduction of several successful Phase II clinical trials on human anti-
interleukin-13/4 monoclonal antibodies such as Anrukinzumab, CNTO 5825, 
Tralokinumab, QAX576, Lebrikizumab and Dupilumab promises their thera-
peutic application in the near future. For some detailed reviews on the IL-13 
role in the evolution of asthma therapy see the paper by Grunig et al. [200] and 
more recent papers by Dunn and Wechsler [206], Legrand and Klion [207] and 
Fahy [208].
Summary and prospective
IL-13 is one of the cytokines which plays an important mediator role in al-
lergic infl ammation. It is also known for contributing directly and indirectly to 
different infl ammatory diseases. The biological properties of IL-13 and its signal-
ling pathways have been characterized and pivotal roles of IL-13 in different 
pathogenic states have been established. It has been well demonstrated that IL-13 
directs many of the important features of airway infl ammation by accumulating 
strong experimental evidences over the years.
This particular cytokine shows important immunomodulatory activities on 
many cell types. However, its activities seem to be more restricted than those of 
IL-4. This behaviour is thought to be related to the distribution of IL-13R. As an 
example, IL-13 does not act on T cells and it is ineffective in directing Th2-cell 
differentiation in contrast to IL-4.
The cytokines produced by allergen-specifi c Th2 cell induce and maintain 
allergic infl ammatory processes and consequently the induction of differentia-
tion of these cells represents the hallmark of allergic diseases.
IL-13 and its signalling pathways are briefl y discussed in this review paper 
but, as mentioned, the precise molecular mechanisms have remained undeter-
mined and require further investigations. Determination of the molecular mecha-
nisms of IL-13 action will allow the development of compounds to target IL-13 
for animal and human therapeutic applications. Finally we should emphasize that 
the intense ongoing investigation in this fi eld will likely yield exciting new tar-
gets for related therapeutic applications.
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